💊 Adalimumab (Humira)
Adalimumab is a biologic medicine given by subcutaneous injection that blocks TNF, an inflammatory substance in the body. It is used to treat several immune-mediated inflammatory conditions such as rheumatoid arthritis, Crohn's disease, ulcerative colitis, and psoriasis. It carries a boxed warning for serious infections and malignancy, so it must be used under a doctor's supervision.
In Arabic: أداليموماب (هيوميرا)🏷️ Brand names & manufacturers
Packages shown are US-market (DailyMed). Brands available in Palestine are in the price section below.✅ What it is used for
- Moderately to severely active rheumatoid arthritis in adults
- Moderately to severely active polyarticular juvenile idiopathic arthritis (age 2 years and older)
- Active psoriatic arthritis in adults
- Active ankylosing spondylitis in adults
- Moderately to severely active Crohn's disease (adults and pediatric patients 6 years and older)
- Moderately to severely active ulcerative colitis (adults and pediatric patients 5 years and older)
- Moderate to severe chronic plaque psoriasis in adults who are candidates for systemic therapy or phototherapy
- Moderate to severe hidradenitis suppurativa (12 years and older)
- Non-infectious intermediate, posterior, and panuveitis (adults and pediatric patients 2 years and older)
🧪 Active ingredient
The active ingredient is adalimumab, a human monoclonal antibody that binds specifically to TNF-alpha and blocks its interaction with cell surface TNF receptors, thereby reducing the inflammation associated with these conditions.
🌿 Benefits
- Reduces signs and symptoms of rheumatoid arthritis and improves physical function
- Inhibits progression of joint damage in rheumatoid and psoriatic arthritis
- Reduces symptoms of Crohn's disease and ulcerative colitis
- Treats plaque psoriasis, hidradenitis suppurativa, and uveitis
📝 How to use
- Given by subcutaneous injection only.
- The dose and duration are set by your doctor or pharmacist based on the condition, age, and weight; do not change it yourself.
- Before and during treatment you must be evaluated for active or latent tuberculosis.
- Some other medicines (such as methotrexate) may be continued alongside it if your doctor decides so.
- Follow your doctor's or pharmacist's instructions on how to inject using the pen or prefilled syringe.
💊 Dosage forms
- Single-dose pen (80 mg/0.8 mL, 40 mg/0.8 mL, 40 mg/0.4 mL)
- Single-dose prefilled glass syringe (80 mg/0.8 mL, 40 mg/0.8 mL, 40 mg/0.4 mL, 20 mg/0.2 mL, 10 mg/0.1 mL)
- Clear, colorless solution
⚠️ Common side effects
- Infections (e.g., upper respiratory infection, sinusitis)
- Injection site reactions (redness, itching, bleeding, pain, or swelling)
- Headache
- Rash
🚨 Serious — seek medical help
- Serious infections that may lead to hospitalization or death, including active tuberculosis, invasive fungal infections, and bacterial, viral, and other opportunistic infections
- Malignancies including lymphoma (some fatal cases reported in children and adolescents) and hepatosplenic T-cell lymphoma
- Anaphylaxis or serious hypersensitivity reactions
- Hepatitis B virus reactivation
- Demyelinating disease (new onset or exacerbation)
- Cytopenias and pancytopenia
- Heart failure (new onset or worsening)
- Lupus-like syndrome or autoimmune hepatitis
⛔ Do not use if
- No contraindications are listed in the FDA label.
❗ Warnings & precautions
- Do not start during an active infection; discontinue if a serious infection or sepsis develops.
- Test for latent TB before and during therapy; treat latent TB before starting.
- For patients with systemic illness who live in or travel to regions where mycoses are endemic, consider empiric antifungal therapy.
- Monitor hepatitis B virus carriers during and for several months after therapy.
- Seek immediate medical attention if symptoms of blood disorders develop.
- Avoid live vaccines during treatment.
- Concomitant use with abatacept, anakinra, or other TNF blockers is not recommended.
- Monitor patients 65 years and older closely for infection or malignancy.
🔄 Drug interactions
- Abatacept: increased risk of serious infection (combination not recommended).
- Anakinra: increased risk of serious infection (combination not recommended).
- Live vaccines: avoid during treatment.
- Other TNF blockers and biologic DMARDs: not recommended due to possible increased infection risk.
- Methotrexate: reduces apparent adalimumab clearance, but no dose adjustment of either drug is suggested.
- Rituximab: higher rate of serious infections observed when a TNF blocker was given afterward.
- CYP450 substrates with a narrow therapeutic index (e.g., warfarin, cyclosporine, theophylline): monitor effect or drug concentration when starting or stopping adalimumab; dose adjustment may be needed.
🤰 Pregnancy
Available studies do not reliably establish an association between adalimumab and major birth defects. Adalimumab is actively transferred across the placenta during the third trimester and may affect the immune response of the exposed infant. Consult your doctor before use during pregnancy or when planning pregnancy.
🍼 Breastfeeding
The lactation section was not included in the label text provided. Consult your doctor before using this medicine while breastfeeding.
🧒 Children
Safety and effectiveness are established for polyarticular JIA (age 2+), Crohn's disease (age 6+), ulcerative colitis (age 5+), hidradenitis suppurativa (age 12+), and uveitis (age 2+). They are not established in pediatric psoriatic arthritis, ankylosing spondylitis, or plaque psoriasis. Lymphoma and other malignancies, some fatal, have been reported in children, adolescents, and young adults treated with TNF blockers. Risks and benefits should be considered before giving live or live-attenuated vaccines to infants exposed in utero.
👴 Older adults
No overall difference in effectiveness was seen between patients 65 years and older and younger adults, but serious infections and malignancies were more frequent in those 65 and older. Consider benefits and risks, and monitor closely for infection or malignancy.
🌡️ Storage
Full storage details were not included in the label text provided. The product is a sterile, preservative-free solution; follow the storage instructions on the package or ask your pharmacist.
⏰ Missed dose
The label text provided gives no specific guidance on missed doses. Contact your doctor or pharmacist for advice, and do not double the dose on your own.
🆘 Overdose
Doses up to 10 mg/kg were given in clinical trials without dose-limiting toxicity. In case of overdose, monitor the patient for signs or symptoms of adverse reactions and institute symptomatic treatment immediately; consider contacting a poison control center or medical toxicologist.
💰 Price & brands in your area
🏛️ Official price in Palestine — Ministry of Health price list:
| Product | Company | Pack | Price |
|---|---|---|---|
| Hyrimoz 40mg/0.8ml 2 PFP Adalimumab 40mg/0.8ml | MASROUJI CO. | 2 Pre- Filled Pen | 2,084 ₪ |
| HYRIMOZ 40MG/0.4ML - 2 PFP Adalimumab | MASROUJI CO. | 2 PFP | 2,114 ₪ |
| HYRIMOZ 40MG/0.4ML - 2 PFS Adalimumab | MASROUJI CO. | 2 PFS | 2,114 ₪ |
📍 Find the nearest pharmacy
Your location is used only in your browser to show nearby pharmacies — we don't store it.
Open in Google Maps👨⚕️ For healthcare professionals
Mechanism of action
Adalimumab binds specifically to TNF-alpha and blocks its interaction with the p55 and p75 cell surface TNF receptors. It also lyses surface TNF-expressing cells in vitro in the presence of complement. It does not bind or inactivate lymphotoxin (TNF-beta). It modulates TNF-regulated biological responses, including adhesion molecule concentrations (ELAM-1, VCAM-1, ICAM-1). Decreases in CRP, ESR, IL-6, MMP-1, and MMP-3 were observed after treatment.
Labeled dosing
Administered by subcutaneous injection; the dose is determined by the treating physician. Adults: RA, PsA, AS 40 mg every other week (some RA patients not on methotrexate may benefit from 40 mg weekly or 80 mg every other week). Crohn's disease and ulcerative colitis: 160 mg Day 1, 80 mg Day 15, then 40 mg every other week from Day 29 (discontinue in UC if no clinical remission by Week 8/Day 57). Plaque psoriasis and uveitis: 80 mg initial dose, then 40 mg every other week starting one week later. Hidradenitis suppurativa: 160 mg Day 1, 80 mg Day 15, then 40 mg weekly or 80 mg every other week from Day 29. Pediatric dosing is weight- and indication-based.
- Evaluate patients for active TB and test for latent infection before and periodically during therapy.
- Limitation of use in ulcerative colitis: effectiveness not established in patients who lost response to or were intolerant of TNF blockers.
- Methotrexate, other non-biologic DMARDs, glucocorticoids, NSAIDs, and analgesics may be continued during treatment.
- Boxed warning: serious infections and malignancy (including hepatosplenic T-cell lymphoma).
- Monitor drug effect or concentration when starting/stopping adalimumab in patients on narrow-therapeutic-index CYP450 substrates.
🎓 Key points for students
- Adalimumab is a recombinant human IgG1 monoclonal antibody produced in a Chinese Hamster Ovary (CHO) expression system.
- Targets TNF-alpha; does not bind TNF-beta (lymphotoxin).
- Boxed warning: serious infections (TB, invasive fungal, opportunistic) and malignancy.
- Screen for latent TB before starting and treat it first if present.
- Avoid combination with abatacept, anakinra, other TNF blockers, and live vaccines.
- Most common adverse reactions (>10%): infections, injection site reactions, headache, rash.
EME runs your whole clinic: appointments with WhatsApp reminders, patient files, finance & inventory, a patient portal and a members-price medical store — with your data isolated and protected.
Try EME free How we protect your data❓ FAQ
What is adalimumab used for?
It is used to treat rheumatoid, psoriatic, and juvenile arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis, as prescribed by a doctor.
How is it given?
By subcutaneous injection using a pen or prefilled syringe; the dose is set by your doctor or pharmacist.
Does it increase the risk of infection?
Yes. It increases the risk of serious infections such as tuberculosis and fungal, bacterial, and viral infections. TB is tested for before treatment and infections are monitored during treatment.
What are the common side effects?
Infections (such as upper respiratory infection and sinusitis), injection site reactions, headache, and rash.
Can I receive vaccines during treatment?
Live vaccines should be avoided during treatment. Ask your doctor before receiving any vaccine.
Can it be used during pregnancy?
Adalimumab crosses the placenta in the third trimester and may affect the infant's immune response. Consult your doctor before use.
⚕️ For education only — not a substitute for advice from your doctor or pharmacist. Do not start or stop any medicine without advice. Source: official FDA drug label via openFDA (2025-12), simplified. Updated: 2026-11-15.
Humira🏭 Cordavis Limited
Adalimumab-aacf🏭 Fresenius Kabi USA, LLC